24 Recruiting Advanced Malignant Solid Neoplasm Phase 1 Clinical Trials
Active phase 1 studies for advanced malignant solid neoplasm enrolling across the USA. Verify eligibility and contact site coordinators.
All Advanced Malignant Solid Neoplasm studiesPhase 1 Studies for Advanced Malignant Solid Neoplasm
Akt Inhibitor MK2206 and Hydroxychloroquine in Treating Patients With Advanced Solid Tumors, Melanoma, Prostate or Kidney Cancer
📍 Rutgers Cancer Institute of New Jersey — New Brunswick, New Jersey
View Study & Checklist ➔Methoxyamine, Cisplatin, and Pemetrexed Disodium in Treating Patients With Advanced Solid Tumors or Mesothelioma That Cannot Be Removed by Surgery or Mesothelioma That Is Refractory to Pemetrexed Disodium and Cisplatin or Carboplatin
📍 City of Hope Comprehensive Cancer Center — Duarte, California
View Study & Checklist ➔Dasatinib, Temsirolimus, and Cyclophosphamide in Treating Patients With Advanced, Recurrent, or Refractory Solid Tumors
📍 M D Anderson Cancer Center — Houston, Texas
View Study & Checklist ➔Testing the Sequential Combination of the Anti-cancer Drugs Olaparib Followed by Adavosertib (AZD1775) in Patients With Advanced Solid Tumors With Selected Mutations and PARP Resistance, STAR Study
📍 UT MD Anderson Cancer Center — Houston, Texas
View Study & Checklist ➔Testing the Biological Effects of DS-8201a on Patients With Advanced Cancer
📍 National Cancer Institute Developmental Therapeutics Clinic — Bethesda, Maryland
View Study & Checklist ➔Niraparib, Temozolomide and Atezolizumab in Treating Patients With Advanced Solid Tumors and Extensive-Stage Small Cell Lung Cancer With a Complete or Partial Response to Platinum-Based First-Line Chemotherapy
📍 UCLA / Jonsson Comprehensive Cancer Center — Los Angeles, California
View Study & Checklist ➔EphA2 siRNA in Treating Patients With Advanced or Recurrent Solid Tumors
📍 M D Anderson Cancer Center — Houston, Texas
View Study & Checklist ➔Avelumab, Utomilumab, Anti-OX40 Antibody PF-04518600, and Radiation Therapy in Treating Patients With Advanced Malignancies
📍 M D Anderson Cancer Center — Houston, Texas
View Study & Checklist ➔Testing the Addition of an Anti-cancer Drug, Copanlisib, to the Usual Immunotherapy (Nivolumab With or Without Ipilimumab) in Patients With Advanced Solid Cancers That Have Changes in the Following Genes: PIK3CA and PTEN
📍 Dana-Farber Cancer Institute — Boston, Massachusetts
View Study & Checklist ➔Veliparib and Dinaciclib in Treating Patients With Advanced Solid Tumors
📍 Beth Israel Deaconess Medical Center — Boston, Massachusetts
View Study & Checklist ➔Testing the Combination of the Anti-cancer Drugs Copanlisib, Olaparib, and MEDI4736 (Durvalumab) in Patients With Advanced Solid Tumors With Selected Mutations
📍 Keck Medicine of USC Buena Park — Buena Park, California
View Study & Checklist ➔Riluzole and Sorafenib Tosylate in Treating Patients With Advanced Solid Tumors or Melanoma
📍 Rutgers Cancer Institute of New Jersey — New Brunswick, New Jersey
View Study & Checklist ➔FID-007 in Treating Participants With Advanced Solid Tumors
📍 Los Angeles General Medical Center — Los Angeles, California
View Study & Checklist ➔Talazoparib and Palbociclib, Axitinib, or Crizotinib for the Treatment of Advanced or Metastatic Solid Tumors, TalaCom Trial
📍 M D Anderson Cancer Center — Houston, Texas
View Study & Checklist ➔Testing How the Body Responds to the Drug CBX-12 in Patients With Advanced Solid Cancers
📍 National Cancer Institute Developmental Therapeutics Clinic — Bethesda, Maryland
View Study & Checklist ➔Trifluridine/Tipiracil and Talazoparib for the Treatment of Patients With Locally Advanced or Metastatic Colorectal or Gastroesophageal Cancer
📍 Roswell Park Cancer Institute — Buffalo, New York
View Study & Checklist ➔Phase I/II Randomized Study of NBTXR3 Activated by Abscopal or RadScopal Radiation in Combination With Immunotherapy (Anti-PD-1/L-1) for Patients With Advanced Solid Malignancies
📍 M D Anderson Cancer Center — Houston, Texas
View Study & Checklist ➔Testing A New Anti-cancer Drug Combination, Entinostat and ZEN003694, for Advanced and Refractory Solid Tumors
📍 Yale University — New Haven, Connecticut
View Study & Checklist ➔TR-002 for the Treatment of Advanced Unresectable Metastatic Solid Tumors Unresectable or Metastatic, Refractory Pancreatic Adenocarcinoma
📍 University of California Davis Comprehensive Cancer Center — Sacramento, California
View Study & Checklist ➔Axatilimab in Combination With Retifanlimab and Paclitaxel for the Treatment of Patients With Advanced or Metastatic Solid Tumors
📍 OHSU Knight Cancer Institute — Portland, Oregon
View Study & Checklist ➔Testing the Combination of Two Anti-cancer Drugs, Peposertib (M3814) and Tuvusertib (M1774) for Advanced Solid Tumors
📍 National Cancer Institute Developmental Therapeutics Clinic — Bethesda, Maryland
View Study & Checklist ➔Testing the Combination of the Anti-Cancer Drugs Temozolomide and M1774 to Evaluate Their Safety and Effectiveness
📍 UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care — Irvine, California
View Study & Checklist ➔Testing the Combination of the Anticancer Drugs ZEN003694 and Binimetinib in Patients With Advanced/Metastatic or Unresectable Solid Tumors With RAS Alterations and Triple Negative Breast Cancer
📍 Boston Medical Center — Boston, Massachusetts
View Study & Checklist ➔A Trial of RSC-1255 for Treatment of Patients With Advanced Malignancies
📍 University of California, Los Angeles (UCLA) Department of Medicine - Hematology/Oncology — Los Angeles, California
View Study & Checklist ➔